307 related articles for article (PubMed ID: 16027139)
1. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
2. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
3. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
4. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
[TBL] [Abstract][Full Text] [Related]
5. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines.
Lin H; Nieda M; Nicol AJ
Eur J Immunol; 2004 Oct; 34(10):2664-71. PubMed ID: 15368282
[TBL] [Abstract][Full Text] [Related]
6. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
[TBL] [Abstract][Full Text] [Related]
7. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity.
Molling JW; Moreno M; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
J Immunol Methods; 2007 Apr; 322(1-2):70-81. PubMed ID: 17343874
[TBL] [Abstract][Full Text] [Related]
8. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
9. Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2.
Ikarashi Y; Iizuka A; Heike Y; Yoshida M; Takaue Y; Wakasugi H
Immunol Lett; 2005 Nov; 101(2):160-7. PubMed ID: 16054231
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 regulates T helper 1 or 2 immune responses of human cord blood CD4+ V alpha 24+V beta 11+ natural killer T cells.
Fujibayashi Y; Fujimori Y; Kasumoto I; Kai S; Hara H; Okamura H; Tsutsui H; Ogawa H; Nakanishi K
Int J Mol Med; 2007 Aug; 20(2):241-5. PubMed ID: 17611643
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis.
Shibolet O; Kalish Y; Klein A; Alper R; Zolotarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
J Leukoc Biol; 2004 Jan; 75(1):76-86. PubMed ID: 14557387
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
13. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
[TBL] [Abstract][Full Text] [Related]
14. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
Azuma T; Takahashi T; Kunisato A; Kitamura T; Hirai H
Cancer Res; 2003 Aug; 63(15):4516-20. PubMed ID: 12907625
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
16. Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells.
Imataki O; Heike Y; Ishida T; Takaue Y; Ikarashi Y; Yoshida M; Wakasugi H; Kakizoe T
J Immunother; 2006; 29(3):320-7. PubMed ID: 16699375
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
[TBL] [Abstract][Full Text] [Related]
18. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases.
Molling JW; Moreno M; de Groot J; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Immunol Lett; 2008 Jun; 118(1):36-43. PubMed ID: 18405982
[TBL] [Abstract][Full Text] [Related]
19. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
20. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL.
Chattopadhyay S; Chakraborty NG
Hum Immunol; 2005 Aug; 66(8):884-91. PubMed ID: 16216672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
